Please ensure Javascript is enabled for purposes of website accessibility

1 Genetics Stock to Put on Your Radar

By Matthew Frankel, CFP® and Brian Orelli, PhD - Updated Jun 23, 2021 at 9:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some of our experts think this stock has tons of long-term potential.

In the pharmaceutical space, there is clearly a lot of potential when it comes to genetics. In this Fool Live video clip, recorded on May 24, Fool.com healthcare and cannabis bureau chief Corinne Cardina, along with Fool.com contributor Brian Orelli, PhD, and chief growth officer Anand Chokkavelu, discuss why CRISPR Therapeutics (CRSP 1.09%) could be such an interesting opportunity for investors. 

Anand Chokkavelu: Anyway, let's talk about these three. We've kind of talked about the space in general, but each one is targeting different applications or diseases. Which ones are each of these companies going after?

Corinne Cardina: I can start and then Brian can add on and give a more scientific answer. We'll keep going alphabetically. We'll start with CRISPR. I'm going to mostly focus on what these companies have in the clinic and just briefly mention anything a little bit further out in their pipeline that's either pre-clinical or in R&D still, but in the clinic, CRISPR Therapeutics is focused on genetic blood disorders, that is sickle cell disease as well as transfusion-dependent beta-thalassemia, and they also have several candidates in immuno-oncology. Further out, CRISPR is exploring type 1 diabetes, it is also exploring in vivo approaches for cystic fibrosis, Duchenne muscular dystrophy, and some other rare diseases. For the most part, CRISPR is not doing in vivo, they are doing ex vivo, where the patient stem cells are removed from their body, reengineered in the lab, and then reintroduced into the patient's body. Sickle cell disease is a large market in the U.S., 100,000 people in the U.S. are estimated to have it. Brian can tell us a little bit more about sickle cell disease, but beta-thalassemia is a slightly smaller market. If you zoom out and look worldwide, 300,000 cases of sickle cell disease and about 60,000 cases of beta-thalassemia. So I'll let Brian jump in on CRISPR here.

Brian Orelli: What's interesting here is that both of these diseases, sickle cell disease and beta-thalassemia are caused by the lack of hemoglobin. Instead of putting hemoglobin back into the cells, what they're actually doing is knocking out a gene that is responsible for turning off the expression of fetal hemoglobin. When we're born, we go from expressing fetal hemoglobin to expressing adult hemoglobin. What they're doing is they're knocking out the gene that does that control and by knocking it out now you get expression of the fetal hemoglobin and then that results in the cells being functional where they weren't before.

Cardina: Brian already touched on this, but sickle cell disease, it doesn't really have an approved treatment. Most of the medical care for patients who have sickle cell disease is focused on symptom management and those symptoms are really severe in terms of impacting quality of life. It can result in anemia, infection, pain, fatigue, it can stunt your development, it also can result in early death. A lot of these patients, they need frequent blood transfusions and they are also hospitalized frequently because of vaso-occlusive crisis, which I believe is like a blockage in the blood. Like Brian said, these companies are targeting where there's basically a vacuum, there's a really need for treatment and ideally a cure, which is what CRISPR is going after here.

Anand Chokkavelu, CFA owns shares of CRISPR Therapeutics. Brian Orelli, PhD has no position in any of the stocks mentioned. Corinne Cardina has no position in any of the stocks mentioned. Matthew Frankel, CFP has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$78.31 (1.09%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.